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Background: The role of AID/APOBEC proteins in the mammalian immune response against retroviruses and
retrotransposons is well established. G to A hypermutations, the hallmark of their cytidine deaminase activity, are
present in several mammalian retrotransposons. However, the role of AID/APOBEC proteins in non-mammalian
retroelement restriction is not completely understood.
Results: Here we provide the first evidence of anti-retroelement activity of a reptilian APOBEC protein. The green
anole lizard A1 protein displayed potent DNA mutator activity and inhibited ex vivo retrotransposition of LINE1 and
LINE2 ORF1 protein encoding elements, displaying a mechanism of action similar to that of the human A1 protein. In
contrast, the human A3 proteins did not require ORF1 protein to inhibit LINE retrotransposition, suggesting a differential
mechanism of anti-LINE action of A1 proteins, which emerged in amniotes, and A3 proteins, exclusive to placental
mammals. In accordance, genomic analyses demonstrate differential G to A DNA editing of LINE retrotransposons in
the lizard genome, which is also the first evidence for G to A DNA editing in non-mammalian genomes.
Conclusion: Our data suggest that vertebrate APOBEC proteins differentially inhibit the retrotransposition of LINE
elements and that the anti-retroelement activity of APOBEC proteins predates mammals.
Keywords: G to A hypermutation, AID, APOBEC3, ORF1p, Lizard APOBEC1, Zebrafish LINE2, LINE1, Zebrafish APOBEC2,
Cytidine deaminase, RetrotransposonBackground
Retrotransposons constitute almost half of the human
genome and are considered to be one of the major driv-
ing forces in the evolution of eukaryotic genomes [1].
They are classified into two major types, long terminal
repeat (LTR) retrotransposons, which include retrovi-
ruses, and non-LTR retrotransposons [2]. The non-LTR
retrotransposon LINE1 (L1) and LINE2 (L2) clades, which
are widespread among vertebrates, differ in two important
structural and functional characteristics. First, the L1 retro-
transposon carries two open reading frames (ORF) encod-
ing ORF1p, an RNA binding protein [3-7], and ORF2p,
a polyprotein with endonuclease and reverse transcriptase
activity [8-10]. In contrast, the L2 retrotransposons can* Correspondence: nika.lovsin@fkkt.uni-lj.si
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reproduction in any medium, provided the orencode either one (ORF2p) or two ORF proteins [11,12],
ORF1p being expendable for retrotransposition in cultured
cells [13]. Second, unlike the L1 reverse transcriptase that
can mobilize other RNA species [14-16], the L2 enzyme is
specific for its own 3′ UTR [12,17]. Furthermore, while
both L1 and L2 elements are present in fish, amphibians
and reptiles [18-20], only the L1 retrotransposon clade
has greatly expanded in mammals [21], reaching 17% of
the human genome [22]. In contrast, the L2 retrotran-
sposons are inactive in placental mammals, with only
highly defective copies present in the human genome
[18,22]. In fact, a massive reduction in the diversity of
active LINE retrotransposon families occurred during the
evolution of tetrapod genomes (summarized in Figure 1).
This ancient conflict between the retroelements and
their hosts has driven the evolution of many host
defense systems (reviewed in [2]), one of them being the
AID/APOBEC proteins.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Phylogenetic relationships between the AID/APOBEC proteins and LINE retrotransposon families in various vertebrates. The
scheme shows different clusters of AID/APOBEC family members identified in various vertebrates and LINE retrotransposons present in their
genomes. The genomes and/or AID/APOBEC proteins analyzed in this study are marked green, and the absence of A5 protein in platypus and
birds is marked with a grey line. The presence of the only A1 homologs identified in non-mammalian genomes so far, green anole lizard and
zebra finch A1 proteins, is marked with an orange line. Data was derived from previous studies [18,20-34]. One unit on the timeline represents
100 million years. MYA, millions years ago.
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http://www.retrovirology.com/content/10/1/156AID/APOBEC protein family members are cytidine
deaminases (CDA) that convert cytidine to uridine in
DNA and RNA [23]. They emerged at the origin of ver-
tebrates and have spread throughout the vertebrate
lineage (summarized in Figure 1). The early ancestors
of AID/APOBEC proteins have been identified in jawless
and cartilaginous fish and include the activation-induced
deaminase (AID), important for antibody diversification,
and the APOBEC2 (A2) protein, involved in active demeth-
ylation and muscle development [35-38]. In amphibians,
APOBEC4 (A4) and APOBEC5 (A5) proteins emerged, but
their functions are yet to be identified [23,24,26]. During
the tetrapod evolution, duplications of AID genes led to the
development of APOBEC1 (A1) [24,35,39-41]. In placental
mammals the APOBEC3 (A3) genes evolved and greatly
expanded. While one gene is present in mice, there are 7
human A3 genes: A3A, A3B, A3C, A3D, A3F, A3G and
A3H [24,29-31,35,42,43]. A3 proteins inhibit various viruses
by introducing C to U mutations in viral cDNA intermedi-
ates leading to G to A hypermutations and viral inhibition
(reviewed in [44]). Alternatively, A3 proteins may inhibit
retroviruses and LINE elements by inhibiting reverse
transcription [45-48]. A3 proteins have been shown to
inhibit many LTR and non-LTR retrotransposons [49-54],
but also various mammalian A1 and pre-mammalian AID
proteins exhibit an activity against the human L1 (hL1)
retrotransposon [55,56]. Moreover, the effects of AID/
APOBEC CDA activity have been identified in the se-
quence of several mammalian LTR and non-LTR retro-
transposons [57,58], but not yet in non-mammalian
genomes, which lack A3 proteins. Recently, it has been
shown that the lizard A1 protein possesses DNA deam-
inase activity [24], which is consistent with the hypoth-
esis that the original function of AID/APOBEC familyof enzymes is retroelement restriction, rather than antibody
diversification [59].
To examine the hypothesis that retroelement restriction
by APOBEC proteins predates mammals, we performed
comparative analyses of the impact of currently available
vertebrate APOBEC proteins on the retrotransposition of
vertebrate LINE elements and performed genome-wide
DNA editing analyses of vertebrate genomes. We found G
to A DNA hypermutations in green anole lizard retro-
transposons, which is the first evidence of retrotrans-
poson editing in non-mammalian vertebrate genomes.
The green anole lizard A1 protein displayed potent DNA
mutator and anti-retroelement activity, which paralleled
that of the human A1 protein. Our results further reveal a
differential mechanism of action of A1 and A3 proteins
against LINE retrotransposons.
Results
Lizard A1 protein inhibits hL1 and ZfL2-1, but not ZfL2-2,
retrotransposons
The CDA activity of the zebrafish AID protein and its
weak but present anti-retroelement activity, observed against
the hL1 element [56], suggest that zebrafish APOBEC
proteins could also act as inhibitors of retrotransposition,
in particular against zebrafish elements. To test this idea,
a neomycin resistance gene (neo)-based retrotransposition
assay (Figure 2) was performed. Human A1 and A3A pro-
teins, potent hL1 inhibitors [49,51,55], were used as positive
controls. Surprisingly, the zebrafish A2a, A2b and AID pro-
teins had no effect on the retrotransposition of the zebra-
fish L2-1 (ZfL2-1) or L2-2 (ZfL2-2) elements, with A2a and
AID displaying only a very weak inhibitory effect against
the hL1 element (Additional file 1: Figure S2). The level of
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Figure 2 Overview of the neo-based retrotransposition assay in HeLa cells (adapted from [60]) and basal retrotransposition levels.
(A) HeLa cells were transfected with plasmids encoding the neo-marked zebrafish L2-2 (ZfL2-2) [11], human L1 (hL1) (specifically L1.2) [60], zebrafish
L2-1 (ZfL2-1) [11], or eel L2 (UnaL2) [12] retrotransposons. The neomycin resistance cassette (neo), inserted within the 3′ UTR region of each tested
retrotransposon in the opposite direction, is interrupted by an intron from the human γ-globin gene in the sense orientation. Transcription of
the retrotransposon DNA containing the cassette, splicing of the γ-globin intron, reverse transcription and integration in the genome are required for
expression of the neo gene. The number of G418 resistant colonies obtained after 12 days of selection is proportional to the number of successful
retrotransposition events. The position of primers used to discriminate between the intronless and unspliced retrotransposon copies and the sizes of
PCR products are indicated. (B) Representative experimental results obtained in the absence of APOBEC proteins after selection of neomycin resistant
colonies for 12 days. The approximate basal retrotransposition rates of each tested retrotransposon, expressed, in average number of colonies per plate,
were: 4958 (split into 5 plates for counting) for hL1, 782 for ZfL2-2, 54 for ZfL2-1 and 101 for UnaL2 retroelements. pCMV, cytomegalovirus promoter;
SVpA, SV40 poly A signal; f, neo437s primer; r, neo1808as primer. To rule out the possibility that the observed LINE inhibition was due to a non-specific
toxicity of the tested AID/APOBEC proteins, the number of G418 resistant colonies obtained upon co-transfection of HeLa cells with an AID/APOBEC
encoding and a neo-expressing pcDNA3.1 plasmid was determined (Additional file 1: Figure S1) as described in [53] and [61].
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http://www.retrovirology.com/content/10/1/156previously detected using a GFP-based retrotransposition
assay in HEK293 cells [56].
Given that the recently identified lizard A1 protein
displays DNA mutator activity [24], we next asked
whether this non-mammalian APOBEC protein exhibits
anti-retroelement activity. Surprisingly, we found that thetwo natural isoforms of the lizard A1a protein (lizA1F3
and lizA1F8) decrease the retrotransposition rates of hL1
to 70%, thus displaying an inhibition potency similar to that
observed for the human A1 protein (Figure 3). In contrast,
no inhibitory activity against the ZfL2-2 element was


























































Figure 3 Lizard and human A1 proteins inhibit ORF1p encoding hL1 and ZfL2-1, but not ZfL2-2 retrotransposition. (A) HeLa cells were
co-transfected with ZfL2-1, ZfL2-2 or hL1 retrotransposon plasmids and effector plasmids encoding human A3A, human A1 (hA1), or lizard A1a
protein variants F3 and F8 (lizA1F3 and lizA1F8). Relative retrotransposition efficiency was determined by counting the fixed and stained
neomycin resistant colonies, formed after 12 days of G418 selection, and calculated by setting the value obtained for control cells co-transfected
with retrotransposon plasmid and an empty vector at 100%. Data are the means ± SD of three independent experiments. ***P < 0.001, **P < 0.01,
*P < 0.05, t-test. (B) The expression of Myc epitope-tagged lizard proteins in mammalian cells was confirmed in the HEK293T cell model by
immunoblotting. GAPDH expression levels were used as a loading control.
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fect comparable with that exhibited against the hL1
retrotransposon. The tested proteins were not cytotoxic
(Additional file 1: Figure S1) and had no effect on the
transfected plasmid DNA (Additional file 1: Figure S5) or
the expression from it (Additional file 1: Figure S6). Since
one of the major differences between the ZfL2-1 and
ZfL2-2 retrotransposons is the absence of ORF1p in the
latter [11], our results suggest that the presence of ORF1p
contributes to the inhibition of LINE retrotransposons by
A1 proteins. Our results clearly suggest a role for lizard
A1 proteins in anti-retroelement defense.
Zebrafish A2b and lizard A1 proteins exhibit DNA
mutator activity
To confirm the recently reported DNA mutator activity of
the lizard A1 protein [24] and to examine the possibility
that the zebrafish A2 proteins also possess CDA activity,
we employed the bacterial rifampicin fluctuation assay. Mu-
tations in the bacterial rpo gene induced by an active DNA
deaminase transiently expressed in bacteria were quantified
by measuring the number of rifampicin resistant (RifR) col-
onies [62-64]. Expression of the anole lizard A1 F3 protein
led to a 77-fold increase in mutational frequency, while
the A1 F8 protein caused a 156-fold increase over control
values obtained with an empty plasmid (Figure 4D).
Zebrafish and human AID proteins increased the muta-
tional frequency 5.6- and 4-fold, respectively (Figure 4B),
which accords with previous reports [56,62]. Whereas
the expression of the zebrafish A2b protein in E. coli
cells resulted in a 12-fold higher mutational frequency
(Figure 4D), the zebrafish A2a protein had a negligible
effect on the number of RifR colonies (Figure 4B).
For all proteins, the mutator activity was enhanced in
the absence of uracil-DNA glycosylase (UDG)(compare Figure 4A with B, and C with D). Our results
demonstrate that the zebrafish A2b and lizard A1 proteins
are potent DNA mutators.
Human A3 proteins inhibit ZfL2-2 retrotransposition
Based on the activity of the human A3A protein
against ZfL2-2 and ZfL2-1 (Figure 3 and Additional file 1:
Figure S2), we hypothesized that other human A3 proteins
can also inhibit L2 elements such as the zebrafish ZfL2-2
and eel L2 (UnaL2) retrotransposons. Indeed, both fish L2
retrotransposons were most potently inhibited by the A3A
and A3B proteins, that decreased the retrotransposition
efficiency of the ZfL2-2 retrotransposon to 5% and 35%,
and of the UnaL2 retrotransposon to 10% and 25%, re-
spectively (Figure 5 and Additional file 1: Figure S3).
The human A3C and A3F proteins also inhibited ZfL2-2
retrotransposition, but to a lesser extent, and did not
affect UnaL2 retrotransposition significantly. The human
A3G and mouse A3 proteins (Figure 5), as well as the
human A2, AID, A3D and A3H-L (haplotype I) proteins
(Additional file 1: Figure S4) had no significant inhibitory
activity against the ZfL2-2 retrotransposon. Notably,
the inhibitory potencies of human A3 proteins against
the fish L2 retrotransposons were comparable to those
against the hL1 retrotransposon, as observed by us
(Figure 5, and Additional file 1: Figures S2–S4) and others
[49,51,53,65,66]. Any significant degradation of transfected
ZfL2-2 plasmid DNA by A3 proteins in the retrotranspo-
sition assays, as reported for the human A3A protein and
foreign DNA [67], was excluded using quantitative real-
time PCR (qPCR) analysis (Additional file 1: Figure S5).
Additionally, the A3A and A3B proteins were only slightly
toxic to the cells during the long period of selection re-
quired for the retrotransposition assay (Additional file 1:
Figure S1), and had no effect on plasmid transcription






































































































Figure 4 DNA editing activities of various AID and APOBEC proteins determined with the E. coli mutator assay. (A, C) Frequencies of
rifampicin resistant (RifR) colonies in KL16 (ung+) E. coli cultures carrying human AID (hAID), zebrafish AID (zfAID), zebrafish A2a (zfA2a), zebrafish
A2b (zfA2b) and lizard A1 variants F3 (lizA1F3) and F8 (lizA1F8) expression plasmids or the vector as control. (B, D) Mutation frequencies of
BW310 (ung-1) E. coli cultures expressing AID/APOBEC proteins or a vector control as in A and C, but note the larger scale on the y-axis. Each
point represents the mutation frequency of an independent overnight culture. Median mutation frequencies are indicated.
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http://www.retrovirology.com/content/10/1/156(Additional file 1: Figure S6), thus confirming bona fide
retrotransposon restriction mechanisms. Altogether, we
demonstrate that human A3A and A3B proteins are po-
tent inhibitors of ZfL2-2 and UnaL2 retrotransposition in
HeLa cells, and that the human A3 proteins inhibit L1






















































Figure 5 Human A3A, 3B, 3C and 3F proteins restrict ZfL2-2 retrotran
retrotransposition of hL1, ZfL2-2 and UnaL2 retrotransposons. HeLa cells we
and 1 μg of retrotransposon target plasmid. Relative retrotransposition effic
resistant colonies, formed after 12 days of G418 selection (Additional file 1:
cells co-transfected with retrotransposon plasmid and an empty vector at 1
experiments. ***P < 0.001, **P < 0.01, *P < 0.05, t-test. (B) The expression of
the HEK293T model by immunoblotting. GAPDH protein levels were usedIntact A3A active site is required for ZfL2-2 inhibition
Since the human A3 proteins inhibited both L1 and L2
elements, we hypothesized that there are common struc-
tural features of A3 proteins required for their inhibition.
To determine if the integrity of the active site residues













sposition. (A) Inhibitory effect of mouse and human A3 proteins on
re co-transfected with 1 μg of the indicated APOBEC effector plasmid
iency was determined by counting the fixed and stained neomycin
Figure S3), and calculated by setting the value obtained for control
00%. Data are the means ± SD of at least three independent
HA, Myc, or V5 epitope-tagged proteins tested in (A) was confirmed in
as a loading control.
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http://www.retrovirology.com/content/10/1/156inhibition, as shown previously for hL1 inhibition [49,51,53],
the retrotransposition assay was performed with two ac-
tive site A3A mutants (E72A and CC101,106AA) that
lack CDA activity [49,51]. The mutations completely abol-
ished the inhibitory activity of the A3A protein against the
ZfL2-2 retrotransposon (Figure 6A), which was confirmed
in a dose-dependent experiment (Figure 6B). To further
examine the role of A3A enzymatic activity in ZfL2-2 in-
hibition, we mutated two other structurally conserved res-
idues F75 and F95, essential for deaminase activity in the
A1 protein, but differentially affecting the CDA activity of
A3A [68,69]. Namely, while only the A3A F95L mutant
displayed deaminase activity in vitro, both F75L and F95L
mutants retained their ability to restrict adeno-associated-
virus replication [68]. Interestingly, both mutants decreased
the retrotransposition rates of the ZfL2-2 retrotransposon
to 40% (Figures 6A and C). Although the lack of deaminase





































































































































Figure 6 Intact catalytic site is required for ZfL2-2 inhibition by the h
ZfL2-2 plasmid and (A) 1 μg of plasmid encoding the A3A effector or its E7
of A3A and its catalytic site mutants E72A and CC101,106AA, or (C) 2, 0.5 a
resistant colonies, formed after G418 selection, were fixed, stained and cou
the value obtained for cells co-transfected with the retrotransposon plasmi
activity (CDA), or lack thereof, of each protein is designated with + or – (1,
from 293T cells transiently expressing HA epitope-tagged proteins. GAPDH
of at least three independent experiments. ***P < 0.001, **P < 0.01, *P < 0.0in cellular ex vivo assays, this indicates that A3A enzymatic
activity is dispensable for ZfL2-2 inhibition, which is in ac-
cordance with a recent report showing that the determi-
nants of A3A CDA activity and anti-hL1 activity are not
the same [70]. Our results thus suggest that while an intact
active site of the A3A protein is required for successful in-
hibition of ZfL2-2, enzymatic activity may not be necessary.
The integrity of at least one A3B domain is required for
ZfL2-2 inhibition
To investigate whether the enzymatic activity of the A3B
protein is important for the inhibition of ZfL2-2 retrotran-
sposition, as previously observed for hL1 inhibition [51,65],
we employed several A3B mutants. The A3B protein pos-
sesses two catalytically active domains with a CDA consen-
sus site, the N-terminal domain (NA3B) with nucleic acid
binding function, and the C-terminal domain (CA3B)
responsible for enzymatic activity [71]. Interestingly,C
GAPDH

































































uman A3A protein. HeLa cells were co-transfected with 1 μg of target
2A, CC101,106AA, F75L and F95L mutants, (B) 2, 1, 0.5, 0.1 and 0.01 μg
nd 0.1 μg of A3A and its F75L and F95L mutants. Neomycin
nted, and relative retrotransposition efficiency was calculated by setting
d and an empty vector at 100%. The reported cytidine deaminase
ref. [49]; 2, ref. [68]). Western blotting was performed using extracts
protein levels were used as loading controls. Data are the means ± SD
5, t-test.
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http://www.retrovirology.com/content/10/1/156the single domain mutants CA3B and NA3B inhibited
ZfL2-2 retrotransposition with a potency similar to that of
the wild-type A3B protein (Figure 7), suggesting that either
domain is sufficient for the inhibition. The inhibitory effect
of the NA3B mutant, confirmed by a dose-dependent
retrotransposition assay (Figure 7B), was completely alle-
viated when the glutamate residue in the consensus site































































































































Figure 7 At least one A3B domain with catalytic site integrity is
necessary for ZfL2-2 inhibition. HeLa cells were co-transfected
with 1 μg of target ZfL2-2 plasmid and (A) 1 μg of effector plasmid
coding for the wild-type A3B protein or its mutants, or (B) 2, 0.5 and
0.01 μg of plasmids encoding the A3B protein and its C-terminal
deletion mutant, NA3B. Relative retrotransposition efficiency was
determined by counting the fixed and stained neomycin resistant
colonies, formed after 12 days of G418 selection, and calculated by
setting the value obtained for control cells co-transfected with
retrotransposon plasmid and an empty vector at 100%. The reported
cytidine deaminase activity (CDA), or lack thereof, of each protein is
designated with + or – (1, ref. [51]; 2, ref. [71]). Western blotting was
performed using extracts from 293T cells transiently expressing HA
and Myc epitope-tagged proteins. GAPDH protein levels were used
as loading controls. Data are the means ± SD of at least three
independent experiments. ***P < 0.001, **P < 0.01, *P < 0.05, t-test.Furthermore, the A3B E68Q and A3B E255Q mutants,
with N- and C-terminal domain-specific impairment
of CDA activity [71], respectively, only partially restricted
ZfL2-2 retrotransposition, while the double mutant A3B
EE68, 255QQ completely lost the inhibitory activity,
strongly suggesting that the enzymatic activity of at least
one A3B domain is required for ZfL2-2 restriction. These
results clearly show that the integrity of one A3B domain
is sufficient and suggest that A3B CDA activity is neces-
sary for the ZfL2-2 inhibition.
A3, but not A1 and A2, proteins decrease the amount of
novel LINE DNA copies
The human A3A and A3B proteins inhibit hL1 retro-
transposition by decreasing the number of novel hL1
DNA [54,55,65,66,69]. To determine whether APOBEC-
induced ZfL2-2 inhibition is due to a similar mechanism,
the effects of A3A and A3B proteins and their mutants on
the amount of novel ZfL2-2 DNA copies were determined
by qPCR (Figure 8). The specificity of the primers spanning
the exon-exon junction, targeting spliced and reverse-
transcribed neo fragments, thus enabling a detection of
both newly integrated ZfL2-2 genomic copies and
novel ZfL2-2 cDNA, was confirmed (Additional file 1:
Figure S8). Our results demonstrate that the human
A3A and A3B proteins, as well as the single domain
NA3B mutant, that all potently inhibit ZfL2-2 retrotran-
sposition (Figures 5, 6 and 7), also decrease the level of
novel ZfL2-2 DNA (Figure 8A). The enzymatically inactive
A3A mutants, that were ineffective in the ZfL2-2 retro-
transposition assay (Figure 6), did not significantly affect
the amount of novel ZfL2-2 DNA copies (Figure 8A), con-
firming that the anti-retroelement activity and the de-
crease in ZfL2-2 DNA are a consequence of wild type
A3A protein expression. Even though foreign DNA deg-
radation by A3 proteins has been suggested previously
[67], the effect observed on the level of cDNA was due
neither to significant plasmid degradation (Additional
file 1: Figure S5A) nor to a decrease in expression from
the plasmid (Additional file 1: Figure S6A). This is in
agreement with the dominant effect of the A3A protein
on the inhibition of hL1 retrotransposition rather than on
hL1 plasmid degradation reported previously [69]. Since
the impact of A3 proteins on the level of novel retrotrans-
poson DNA (Figure 8) corresponds to the results of the
retrotransposition assay (Figures 5, 6 and 7), we suggest
that the inhibition of ZfL2-2 retrotransposon occurs at the
reverse transcription and/or at the integration step.
Interestingly, despite their anti-retroelement activity
against hL1 (Figure 3), the lizard and human A1 pro-
teins did not change significantly the level of novel hL1
or ZfL2-2 DNA (Figure 8B). The possibility of A1 pro-
teins affecting the level of the transfected plasmid or




























































































































Figure 8 A3A and A3B, but not A1 or A2, proteins decrease the amount of novel ZfL2-2 DNA. (A, B) Total cellular DNA was extracted
from HeLa cells after 4 days of hygromycin selection following transfection with plasmids encoding ZfL2-2 or hL1 retrotransposons and the
indicated APOBEC effector plasmids (1 μg of each). Isolated DNA was subjected to qPCR for specific quantification of intronless amplicons from
the spliced neo cassette corresponding to both integrated and de novo synthesized retrotransposon DNA. Values obtained with DNA from cells
transfected with an empty vector were set as 1. Histogram bars represent the means ± SD of two independent experiments. Mock controls
represent untransfected cells. ***P < 0.001, **P < 0.01, *P < 0.05, t-test.
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S5B and S6B). Our results thus suggest that the inhib-
ition of hL1 retrotransposition by A1 proteins does not
include significant alterations in the amount of novel
retrotransposon DNA, thus implying that lizard and hu-
man A1 proteins do not interfere with the stability or
the synthesis of the retrotransposon DNA.
Novel ZfL2-2 and hL1 DNA copies are not hypermutated
We next asked whether any mutations might have occurred
in the novel spliced ZfL2-2 and hL1 DNA copies in the
presence of zebrafish, lizard, mouse or human APOBEC
proteins. The overall mutation rates were very low and
there was no apparent increase in G to A mutations
(Additional file 1: Figure S7), indicating that neither of
the tested AID/APOBEC proteins edits the novel retro-
transposon DNA during the course of reverse tran-
scription or integration. This is in accordance with
previous studies showing that the inhibition of hL1 by
human AID/APOBEC proteins occurs in the absence
of hypermutations [49,51,53-55,66]. Although we can-
not exclude the possibility of rapid degradation by host
proteins of any highly mutated copies, or occurrence
of mutations outside of the neo gene, our results sug-
gest that the novel ZfL2-2 and hL1 DNA copies gener-
ated in the presence of the tested APOBEC proteins
are not hypermutated.
Genome-wide analysis reveals G to A editing in lizard
retrotransposons
Long clusters of G to A DNA mutations, a hallmark of
A3 protein activity, are present in mammalian LTR and
non-LTR retrotransposons [50,57,58,72-74]. Given the
observed potent anti-retroelement (Figure 3) and CDAactivity (Figure 4, [24]) of the lizard A1 protein, we next
assessed whether G to A DNA editing is present in non-
mammalian genomes, using the in silico method described
by Carmi et al. [58]. Retrotransposon classes from zebrafish
(Danio rerio (DR)), green anole lizard (Anolis carolinensis
(AC)) and mouse genomes were screened. Pairwise align-
ments were generated between retrotransposons and
clusters of G to A mutations in the retrotransposon posi-
tive strand indicated editing by AID/APOBEC proteins,
while clusters of C to T mutations served as controls
[58]. A significant level of DNA editing was confirmed in
mouse IAP retrotransposons (Figure 9, Additional file 1),
as expected for this A3 protein encoding genome, and as
observed previously [58]. Importantly, a significant num-
ber of G to A edited elements was found in lizard L1 ret-
rotransposons (85/32872 elements; ~0.26%; 7.5-fold
greater than C to T control), but not in lizard L2, CR1
and LTR elements. On the other hand, a very weak and
possibly negligible editing signal was observed in zebra-
fish retrotransposons (Figure 9, Additional file 1: Tables
S2 and S3). Altogether, our genome-wide analyses provide
the first evidence of G to A editing in a non-mammalian
genome.
Discussion
Our genome analysis provides the first evidence of G to
A editing of retrotransposon DNA in a non-mammalian
vertebrate genome, thus reflecting the presence of editing
competent AID/APOBEC proteins (or other deaminases).
Importantly, we report for the first time a potent anti-
retroelement activity of a reptilian A1 protein, which indi-
cates that this host-defense activity of APOBEC proteins
originates in amniotes. The DNA mutator and anti-

































































































































































































































































































































































































































































































































































































Edited elements - G to A (% of family) Control elements - C to T (% of family)B
Figure 9 Vertebrate genome analysis reveals G to A hypermutations in lizard retrotransposons. LINE and LTR subfamily sequences in
zebrafish (Danio rerio (DR)) and lizard (Anolis carolinensis (AC)) genomes were screened for G to A DNA editing using pairwise alignment to find
clusters of G to A mismatches. C to T clusters were used as a negative control, while mouse IAP retrotransposons, where editing has previously
been detected [58], served as a positive control. Editing rates are summed and presented per family. (A) The number of edited retrotransposons
with G to A or C to T clusters in each family. (C) The number of edited sites in each family. Panel (B) presents the data from (A), normalized by
the number of sequences in each retrotransposon family. Panel (D) presents the data in (C), normalized by the number of base pairs in each
family. Results were produced with the P-value and threshold parameters set to 10–8 and 8, respectively.
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http://www.retrovirology.com/content/10/1/156that they indeed might have been responsible for this
editing. Moreover, we demonstrate that human A3 proteins
inhibit both L1 and L2 retrotransposons in a sequence-
independent manner. In contrast, lizard and human A1
proteins blocked only ORF1p encoding LINE elements,
revealing a differential mechanism of action of A1 and A3
proteins against LINE retrotransposition.
The anti-retroelement activity of A1 proteins
predates mammals
AID/APOBEC proteins are present in all vertebrates
(summary in Figure 1), but their distribution, evolution
and functions differ. Fish genomes encode AID and A2
members of the APOBEC family, but lack the A1 and A3
genes [23]. However, our genomic analyses did not reveal
any DNA editing in zebrafish LINE elements (Figure 9).
In accordance, our data demonstrate that zebrafish AID/APOBEC proteins have a negligible effect on ZfL2-1, ZfL2-
2 and hL1 retrotransposition (Additional file 1: Figure S2).
Along with the low DNA mutator activity of the zebrafish
A2b protein, these results collectively indicate that the
anti-LINE activity of APOBEC proteins evolved later
during vertebrate evolution.
In reptiles and birds, A1 homologs have been discovered
[24]. Here, we confirm previous observations [24] that
the anole lizard A1a protein is a potent DNA mutator
(Figure 4) and show that it inhibits hL1 and ZfL2-1 retro-
transposition (Figure 3), which suggests that the APOBEC
anti-retroelement defense function exists in reptiles. The
turnover of retrotransposons in reptiles is very rapid and
only a few copies of each retrotransposon family are
present in their genomes, suggesting that host factors effi-
ciently prevent their fixation [25]. The identification of the
latter awaits further studies, but our results suggest
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retroelement proteins in reptiles. The lizard A1 pro-
tein is expressed in the gastrointestinal tract and it
lacks the C-terminal region present in mammalian A1
proteins essential for their apoB RNA editing function
[24,41]. It has thus been suggested that the DNA editing
function of A1 proteins predates their ability to modify
RNA in mammals [24]. Therefore, the DNA mutator
and anti-retroelement activity of the lizard A1 pro-
tein, along with the G to A DNA hypermutations detected
in the lizard genome, suggest that the anti-retroelement
activity of A1 proteins emerged in amniotes.
A3 and A1 proteins differentially inhibit LINE
retrotransposition
Our comparative analyses of zebrafish, lizard and human
AID/APOBEC-induced inhibition of hL1, ZfL2-1 and
ZfL2-2 retrotransposons demonstrate that of the human
A3 proteins, A3A and A3B most potently inhibit fish L2
retrotransposition (Table 1), with rates and a mechanism
(Figures 5, 6, 7 and 8) resembling their inhibition of
hL1 [49,51,53,65,66,69]. In fact, several similarities be-
tween A3-induced inhibition of L1 and L2 retrotran-





CDA in E. coli
hL1
A3A + 1 +++ *
A3B + 1,3 +++ *
A3C + 5 ++ *,
A3F + 7 ++ *,
A3D ND, edits viral cDNA 8 – *,4
A3G + 5 – *,4
A3H + 10 – *,11
hA1 + 5 +* / ++
hA2 – 5 – *,2
hAID + 5 – *,6
lizA1aF3 + *,13 + *
lizA1aF8 + *,13 + *
zfAID + *,14 – * / +
zfA2a – * – *
zfA2b + * – *
The basic structural differences of the tested retrotransposons are schematically rep
30% inhibition; ND, not determined; 1, [51]; 2, [49]; 3, [71]; 4, [65]; 5, [62]; 6, [66]; 7,conserved active site (Figure 6); (2) the A3B-induced in-
hibition is likely dependent on enzymatic activity and the
integrity of at least one domain is needed (Figure 7); (3)
A3A and A3B proteins decrease the level of novel retro-
transposon DNA copies (Figure 8A); (4) in novel retro-
transposon DNA copies, no obvious hyperediting was
found (Additional file 1: Figure S7). This suggests that the
A3-induced restriction of L1 and L2 retrotransposons in
HeLa cells occurs in an editing-independent manner, re-
gardless of the presence or absence of ORF1p in the ele-
ments, and includes a decrease in the level of novel
retrotransposon DNA. In contrast, the effect of both lizard
and human A1 proteins on the level of novel retrotrans-
poson DNA was negligible (Figure 8B). Additionally, they
only blocked the ORF1p encoding hL1 and ZfL2-1 ret-
roelements, but not the ZfL2-2 element (Figure 3),
which lacks ORF1p [11,60], suggesting that the inhib-
ition of LINE retrotransposons by A1 proteins is
ORF1p-dependent. ORF1p is an RNA binding protein
that forms ribonucleoprotein particles (RNPs) [3-7,75]
and has been proposed to stabilize L1 RNA [76]. It is
possible that the A1 protein interferes with the retro-
transposition process by affecting these RNPs. Indeed,







,2 +++ * +++ *
,4 +++ * ND
6 ++ * ND




12 – * + *
– * ND
– * ND
– * + *
– * + *
14 – * – *
– * – *
– * – *
resented. *, results of this study; +++, 70% inhibition; ++, 50% inhibition; +,
[77]; 8, [78]; 9, [50]; 10, [31]; 11, [53]; 12, [55]; 13, [24]; 14, [56].
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http://www.retrovirology.com/content/10/1/156molecular-mass RNP complexes in 293T cells [55]. The
absence of ORF1p in the ZfL2-2 retrotransposon could
preclude such interactions and the ability of A1 protein to
inhibit retrotransposition. The selective activity of the hu-
man and lizard A1 proteins against LINE retrotransposons
suggests that the mechanism of anti-retroelement activity
of A1 proteins has been conserved during vertebrate evo-
lution. In summary, our results clearly show that the
mechanism of LINE inhibition by A1 and A3 proteins is
different.
G to A DNA editing identified in a non-mammalian
vertebrate genome
Whole genome analyses have previously provided evi-
dence of DNA editing in LTR and non-LTR retrotran-
sposons in human and mouse genomes [58]. In this
study, a clear G to A editing signal was identified in L1,
but not in L2 retrotransposons of the lizard genome
(Figure 9), despite their high diversity and low fixation
rate [19,20,25]. These findings suggest that some retro-
transposons are/were preferentially edited over others.
Interestingly, both lizard and human A1 proteins inter-
fered with hL1 and ZfL2-1, but not ZfL2-2, retrotran-
sposons in vitro (Figure 3). On the other hand, the rates
of editing observed in L1 and L2 retrotransposons in the
vertebrate genomes analyzed were low. This is in ac-
cordance with the fact that despite the significant inhib-
ition of retrotransposition (Figures 3 and 5), no lizard or
human APOBEC-induced editing was detected in the
novel hL1 DNA (Additional file 1: Figure S7), as shown
previously for human APOBECs [49,51,53-55,66], nor in
ZfL2-2 DNA copies in our ex vivo assays (Additional file
1: Figure S7). Altogether, our results suggest that (1) G
to A DNA editing of retrotransposons predates mam-
mals, (2) that retrotransposons were differentially edited
during evolution, and (3), that, based on the low editing
rates of the vertebrate LINE retrotransposons and ab-
sence of hypermutations in the sequenced LINE copies,
AID/APOBEC proteins may have impacted the evolu-
tionary dynamics of LINE retrotransposons also in an
editing-independent manner.
Conclusion
Altogether, the results of our ex vivo experiments, sum-
marized in Table 1, along with our genomic analyses, in-
dicate that the impact of AID/APOBEC proteins on the
evolution of retrotransposons is broader than previously
thought. The DNA editing detected in the lizard gen-
ome, the DNA mutator and the anti-retroelement activ-
ity of the lizard A1 protein shown here, suggest that the
emergence of A1 proteins in reptiles is associated with
the development of anti-retroelement activity in amni-
otes. Moreover, we observed that human and lizard A1
proteins restricted only ORF1p encoding LINE elements,while the presence of ORF1p was not necessary for anti-
LINE activity of A3 proteins. Additionally, A3, but not
A1, proteins potently restricted LINE retrotransposition
by decreasing the level of novel retrotransposon DNA.
The differential mechanism of LINE inhibition by A1
and A3 proteins, along with the differential editing of
retroelements detected in vertebrate genomes, suggest
that the early evolutionary appearance of APOBEC pro-
teins may have importantly contributed to the different
levels of expansion of LINE elements during evolution




Zebrafish AID, A2a and A2b encoding fragments were
PCR amplified from previously described plasmids [36]
using the primer pairs zAIDKpnIf/zAIDNotIr, zA2aKpnIf/
zA2aNotIr and zA2bKpnIf/zA2bNotIr (Additional file 1:
Table S1), and cloned into the pcDNA6.2 vector (Invitro-
gen). Lizard A1 variants F3 (R73K, Y116C) and F8 (N52D)
coding fragments were amplified with lizA1HindIIIs and
lizA1XhoIas primers from bacterial pTrc99A-based ex-
pression vectors that were a kind gift from prof. Conticello
[24], and subcloned into the pcDNA6.2 plasmid. The AID
and APOBEC bacterial expression plasmids used in the
mutational assay were obtained by subcloning into the
pTrc99A plasmid [63]. Plasmids encoding the full length
hL1 (pJM101 [60]), UnaL2 (pI-29 [12]), ZfL2-2 (pBZ2-5)
and ZfL2-1 (p77.52) [11] retrotransposons, all of them
marked with the neo cassette, were described previously.
Plasmids encoding retrotranspositionally defective retro-
transposons, the ZfL2-2 and ZfL2-1 3′ UTR deletion mu-
tants (pBB4 and p74.18) [11], the hL1 ORF1p mutant
(pJM111) and the ORF2p mutant (pJM105) with no re-
verse transcription activity [60], were used as negative
controls. All retrotransposon plasmids also carried a
hygromycin resistance gene that enabled selection of suc-
cessfully transfected cells. Vectors expressing mouse A3
and human A1, A2, AID, A3C, A3F, A3G, A3D, A3H,
A3H-L, A3A and A3B proteins were prepared from previ-
ously described plasmids [51,78-81]. The plasmids encod-
ing the A3A E72A, CC101,106AA, ECC72,101,106AAA,
F75L and F95L mutants were prepared using the Quick-
Change II Site-Directed Mutagenesis kit (Stratagene) and
the primers A3A.E72Af, A3A.E72Ar, A3A.CC101,106AAf
and A3A.CC101,106AAr, as well as previously reported
primers [68]. NA3B and CA3B mutants encoding frag-
ments were PCR amplified from the pKA3B plasmid
[51,61] using the primer pairs NA3B.HindIIIs/NA3B.
XhoIas and CA3B.HindIIIs/CA3B.XhoIas, respectively,
and cloned into the pcDNA6.2 plasmid. Plasmids en-
coding NA3B E68Q, A3B E68Q, A3B E255Q and A3B
EE68, 255QQ mutants were prepared by site directed
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http://www.retrovirology.com/content/10/1/156mutagenesis using the primers A3B.E68Qs, A3B.E68Qas,
A3B.E255Qs and A3B.E255Qas. All plasmids were verified
by sequencing. All primer sequences can be found in
Additional file 1: Table S1.
E. coli mutation assay
The mutation assay was performed as described pre-
viously [24,63,64] using the E. coli strain KL16 (Hfr
(PO-45) relA1 spoT1 thi-1) and its UDG-deficient de-
rivative (BW310). Briefly, KL16 and BW310 cells were
transformed with AID/APOBEC expression constructs
or vector alone. Individual colonies were picked and
grown to saturation in a liquid LB medium containing
100 μg/ml ampicillin and 1 mM isopropyl 1-thio-β-D-
galactopyranoside (IPTG), with the exception of control
experiments, in which the IPTG inducer was omitted. An
aliquot of saturated culture was plated onto LB medium
containing 100 μg/ml rifampicin and 100 μg/ml ampicillin
to select RifR colonies, and an appropriate dilution was
plated onto LB medium containing 100 μg/ml ampicillin
for viable cell count. All plates were incubated overnight
at 37°C to allow colony formation. Mutation frequencies
were measured by determining the median number of col-
ony forming cells that survived selection per 109 viable
cells plated. Each median was determined from 8–16 in-
dependent cultures. IPTG induced expression of AID and
APOBEC proteins conferred no obvious defect in cell
growth or viability.
Immunoblotting
Human embryonic kidney 293T cells were transfected
with 1 μg of APOBEC encoding plasmid. 48 h after
transfection, cells were lysed in RIPA lysis buffer (1%
NP-40, 0.1% SDS, 150 mM NaCl, 50 mM Tris–HCl,
pH 7.6) with Protease Inhibitor Cocktail (Sigma) and in-
cubated for 40 min at 4°C. After separation of cell lysates
by SDS-PAGE, western blotting using α-HA (Sigma),
α-Myc, α-V5 and α-GAPDH monoclonal antibodies
(Invitrogen) and the appropriate HRP-conjugated sec-
ondary antibodies was performed. Detection with ECL
reagent (Pierce) followed.
Retrotransposition and toxicity assays
The effect of AID/APOBEC proteins on retrotransposi-
tion and their possible cytotoxic effect were measured as
previously described [51,53,60,61]. Briefly, HeLa cells
were seeded in 6-well dishes at a density of 2 × 105 cells
per well, left to attach for 24 h, and co-transfected using
6 μl of Fugene® 6 Transfection Reagent (Roche), with
1 μg of a retrotransposon encoding plasmid (pJM101,
pBZ2-5, or pI-29), or, for cytotoxicity testing, with the
neo-expressing pcDNA3.1 plasmid (Invitrogen) instead,
and with 1 μg of the respective AID/APOBEC protein en-
coding plasmid, or an empty vector (pcDNA6.2). In thecase of the ZfL2-1 retrotransposon, a total of 1.6 × 106
cells per 10 cm plate were seeded and 24 h later co-
transfected with 2.5 μg of each retrotransposon and AID/
APOBEC encoding plasmid. 2 days post-transfection, cells
were reseeded on 10 cm dishes, incubated for 24 h, and
incubated with G418 (500 μg/ml) for the next 12 days. Re-
sistant colonies were fixed with methanol, stained with
trypan blue and counted. Assays with plasmids encoding
the retrotranspositionally defective ZfL2-2 (pBB4) and
ZfL2-1 (p74.18) [11] or hL1 (pJM111 and pJM105) [60]
retrotransposons and plasmids encoding AID/APOBEC
proteins were performed as negative controls. In addition,
cells were transfected only with AID/APOBEC plasmids.
In both cases, no resistant colonies were formed (data not
shown). The retrotransposition rate in the presence of the
empty pcDNA6.2 vector was set to 100%. Retrotransposi-
tion efficiency values are means ± SD from at least three
independent experiments performed in triplicates. Statis-
tical significance between two groups was calculated by
performing the Student’s t-test. A value of P < 0.05 was
considered to be of statistical significance.
DNA isolation with sequencing and qPCR analyses of
novel LINE DNA and plasmid DNA levels
For sequencing and analysis of novel retrotransposon
DNA HeLa cells were co-transfected with 1 μg of APO-
BEC and 1 μg of retrotransposon plasmids as described
above, and transfectants containing the retrotransposon
plasmid were selected with hygromycin (200 μg/ml) for
4 days. Total DNA (both chromosomal and episomal) was
isolated using the DNeasy Blood & Tissue Kit (Qiagen)
and contaminating RNA was degraded with RNase A
from bovine pancreas (Roche).
To analyze the novel retrotransposon DNA for muta-
tions (Additional file 1: Figure S7), 600 ng of DNA per
sample in 20 μl reactions was subjected to Platinum Taq
DNA Polymerase High Fidelity (Invitrogen) PCR ampli-
fication of the neo gene with primers neo437S and
neo1808AS [60]. The integrity of the isolated DNA was
verified by amplification of the single copy PGK gene.
After gel electrophoresis, the intronless neo PCR prod-
ucts were isolated, purified and cloned into pCR4 TOPO
TA cloning vectors (Invitrogen). Plasmids were isolated
from at least 5 individual colonies and the neo insert was
sequenced using T7 primers. Nucleotide sequences of
independent clones were aligned and analyzed using the
Hypermut software [82].
To determine the relative abundance of novel ZfL2-2
and hL1 copies in total DNA, quantitative PCR analysis
was performed. A 117 bp fragment of the spliced and re-
versely transcribed neo gene was amplified with an in-
ternal sense primer (Neo210s) and an exon-exon junction
spanning antisense primer (Neo1228as), which specifically
recognizes the spliced neo cassette. Primers targeting two
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haemoglobin beta (HBB) [83], were used for normalization
of spliced neo DNA levels. All reaction mixtures contained
500 nM of each primer and 2.5 ng of DNA in a final vol-
ume of 10 μl. qPCR was carried out on a LightCycler
Nano system (Roche) using FastStart Essential DNA
Green Master (Roche) chemistry at the following cycle
conditions: one cycle at 95°C for 600 s; 45 cycles at 95°C
for 15 s, 60°C for 12 s, 72°C for 15 s, and one cycle at 72°C
for 120 s. The specificity of each primer pair was con-
firmed by melting curve analysis and gel electrophoresis
following each run (Additional file 1: Figure S8). A calibra-
tor DNA sample, isolated from HeLa cells co-transfected
with the retrotransposon and an empty plasmid was used
for determination of PCR reaction efficiency and for inter-
run variability correction. An established comparative Cq
method with efficiency correction, error propagation and
calibrator normalization was used for relative quantification
using both reference genes [84]. Results are presented rela-
tive to the neo frequency obtained with the DNA sample
isolated from cells co-transfected with an empty vector and
the retrotransposon plasmid.
To test the effect of APOBEC proteins on plasmid
DNA, cells were co-transfected as described above, ei-
ther with the ZfL2-2 encoding plasmid or an empty
pcDNA6.2 vector, and the APOBEC encoding plasmid.
48 h after transfection, total DNA was isolated, and the
effect of APOBEC proteins on plasmid DNA was analyzed
with qPCR. Levels of the ZfL2-2 retrotransposon encoding
plasmid were measured by amplification of a 109 bp frag-
ment using the primer pair Neo673F/Int738R, while
pcDNA6.2 plasmid level was detected with the primer pair
Blas149F/Blas248R amplifying a 100 bp long fragment
within the blasticidin resistance gene. Plasmid levels were
normalized to genomic DNA levels by measuring the
HBB and SOD2 gene levels, and the reaction conditions
were essentially the same as described above, except that
0.025 ng of total DNA was used per reaction. All primer
sequences are listed in Additional file 1: Table S1.
RNA isolation, reverse transcription and qPCR analysis
RNA was isolated 2 days post-transfection using the
RNeasy Plus Mini kit (Qiagen) and contaminating DNA
was degraded using the DNA-free Kit (Ambion). Reverse
transcription was performed in 10 μl reactions with
1.25 μg of each RNA sample using the Superscript Vilo
cDNA Synthesis Kit (Invitrogen). Negative controls
without template or reverse transcriptase were included
in all assays. Resulting cDNA was diluted 4000-fold and
subjected to qPCR analyses with primer pair Neo673F/
Int738R (Additional file 1: Table S1). The GAPDH refer-
ence gene was amplified with the GAPDHf/GAPDHr
primer pair. The reaction conditions were the same as
for the DNA qPCR analysis described above.Genome-wide analysis of G to A editing in vertebrate
genomes
All genomic repeats in the LINE and LTR classes were
downloaded from the UCSC table browser [85] ‘rmsk’
table via the “Galaxy” online genomics tool (http://main.
g2.bx.psu.edu/) [86-88] for mouse, lizard and zebrafish
genomes (mm9, anoCar2 and danRer7 genomic builds,
respectively). Additionally, we downloaded the latter 2 ge-
nomes from the UCSC genome browser’s [89] FTP site
(ftp://hgdownload.cse.ucsc.edu/) and ran RepeatMasker
(http://www.repeatmasker.org) with libraries of repeats
of interest that were not present in the ‘rmsk’ table (see
Additional file 2). The genomic sequences respective to
the coordinates identified by RepeatMasker were extracted
from the genomes and united with the ‘rmsk’ table data.
Retrotransposon sequences of each genome were sorted
by subfamilies. The subfamily annotation was assigned by
RepeatMasker and was derived from Repbase Update’s
[90] three levels of classification that we addressed as
‘Class’, ‘Family’ and ‘Subfamily’ (e.g. LINE class, L1
family, L1_AC_11 subfamily (Additional file 1: Tables
S2 and S3)). The DNA editing detection was performed
using the method described by Carmi et al. [58]. The
method contains two steps: generating pairwise align-
ments of all sequences of the same subfamily using
BLAST [91] and screening the alignments for DNA
editing with PERL scripts. Briefly, pairwise alignments
between similar sequences in LINE and LTR classes of
retrotransposons from the zebrafish, lizard and mouse ge-
nomes were generated using BLAST [91]. The alignments
were then screened for one or more clusters of consecu-
tive G to A mutations, and the resulting editing rates
compared to those previously detected in the human
(L1 and SVA) and mouse genomes (L1 and IAP) [58].
Based on the strand specificity of DNA editing, comple-
mentary event of C to T mutations was used as control.
The goal was to detect pairs of ‘parent’ and ‘child’ se-
quences, where the child has a cluster of G to A mutations
in comparison to the parent, denoting that its DNA was
edited by APOBEC proteins during retrotransposition.
The high similarity we demanded between these two
sequences, enforced by the BLAST parameters (E-value
of 10-50) and our algorithm, provides significant support
that the child sequence indeed evolved from the parent se-
quence. The DNA editing finding algorithm searches for
a pair of sequences with a series, or cluster, of G to
A mismatches. To reduce the false-positive rate, we
do not allow any other type of mismatch in the G to
A cluster. The cluster’s significance is measured by two
values: (i) ‘Threshold’ - the number of G to A mismatches
in the cluster, (ii) ‘P-value’ - the P-value calculated by the
Binomial probability of arbitrarily getting such a cluster of
transitions in the given alignment. The probability of a
single transition is calculated by the number of T to C and
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G to A mutations in the retrotransposon’s positive strand
as defined by its ORF. For control, we exploited this
strand specificity by using the G to A ‘editing’ of the minus
strand to test the significance of our results. Our data con-
tains only the retrotransposon positive strands, thus, this
event is represented as C to T ‘editing’ in our data. We
present the same parameters used by Carmi et al. [58],
which contain a set of parameters with extremely high
significance (P-value = 1e-13 and Threshold = 9) and a
set of slightly relaxed parameters (P-value = 1e-8 and
Threshold = 8). The data in the manuscript was gener-
ated using the latter (for details, see also Additional
files 1 and 2). We applied the method to all LINE
and LTR repeats in the zebrafish and lizard genomes
and compared the results to significantly edited fam-
ilies in human and mouse genomes.Additional files
Additional file 1: A PDF document containing supplemental data
for this paper. Included are eight supplemental figures (Additional file 1:
Figures S1–S8), three supplemental tables (Additional file 1: Tables S1–S3)
and details about the in silico genomic analysis with the information
about dataset construction, analysis of results and description of the
Additional file 2 spreadsheet.
Additional file 2: An Excel spreadsheet (XLS) that corresponds to
the data in Additional file 1, Section 3, Coordinates of editing
detection pairs. The spreadsheet contains all the coordinates of editing
pairs used in our in silico genomic analyses.Abbreviations
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